Defendant
4 cases as defendant.
Natco Pharma Limited ("NATCO") is an Indian pharmaceutical company incorporated in 1981 and headquartered at Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana. It is publicly listed on India's BSE and NSE (ticker NATCOPHARM) and is not a subsidiary. Its FY2024 annual report cites roughly 4,800 employees (other trackers report ~5,000), consolidated revenue of approximately ₹4,127 crore (~US$490 million) and profit after tax of about ₹1,388 crore.
Operations. NATCO is a vertically integrated generics manufacturer spanning active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs). It is best known in India for branded oncology generics—its oncology division launched in 2003 with VEENAT (generic imatinib)—and also markets cardiology, diabetology and CNS products domestically. Internationally it pursues Paragraph IV / first-to-file generic filings (including lenalidomide, semaglutide, olaparib and carfilzomib) largely through out-licensing partnerships with larger generic firms, with key markets in the US, Canada, Brazil and other regions. A smaller Crop Health Sciences division sells agrochemicals. It operates multiple manufacturing units and two R&D centers in India.
Litigation posture. The tracked data show 2 cases as defendant and 0 as plaintiff. That pattern—an entity sued but never suing—is consistent with an operating company rather than a non-practicing entity. Both tracked matters are the same Hatch-Waxman ANDA dispute: Celgene Corp. v. Natco Pharma Ltd., filed 2012-07-20 in the U.S. District Court for the District of New Jersey (appearing twice in the dataset, apparently duplicated). NJ is Celgene's home venue and a common generic-pharmaceutical forum, not a plaintiff-friendly NPE venue like the Eastern District of Texas.
Context. The Celgene suit concerns patents covering lenalidomide (Revlimid), the multiple myeloma drug; NATCO later supplied the generic lenalidomide launch in the US through a partner. Neither case involves a patent-assertion business model, and no evidence indicates NATCO funds or operates patent-assertion entities.
Related patent-infringement action asserting the '517, '230, '740, '569, '357 and '219 patents; consolidated with the 2010 action by order dated November 9, 2012. The narrative could not confirm that the '554 patent was separately asserted in this 2012 action.
Celgene asserted U.S. 7,977,357 against Natco, Arrow, and Watson in a REVLIMID ANDA litigation. The case settled and a consent judgment entered Jan. 4, 2016 dismissed claims with prejudice and enjoined Natco from generic lenalidomide except under license. The May 27, 2014 Markman opinion in the Natco litigation also construed 'Form A' for the '357 and '598 patents.
Celgene asserted US 6,561,976 as an asserted 'Celgene Patent' in an ANDA/Hatch-Waxman suit against Natco and others over generic THALOMID/REVLIMID. A May 7, 2014 stipulation recorded Natco's non-contest of infringement of certain claims of the ’976 patent. The case settled, and the docket terminated on Jan. 5, 2016.
Celgene brought this ANDA patent-infringement suit against Natco, Arrow, and Watson. The '717 patent was added by Fifth Amended Complaint on May 6, 2013, and the case settled on December 22, 2015, with a license to market generic lenalidomide beginning January 31, 2026; the docket terminated January 5, 2016.